Novartis India downgraded to strong sell amid valuation concerns
after close1 source ↓written by the desknot a recommendation
Novartis India has been downgraded to strong sell due to valuation concerns, shifting from fair to expensive. The stock trades at a P/E ratio of 215.7, with a P/B ratio of 2.71, indicating a premium valuation. Additionally, the PEG ratio of 1.70 raises sustainability concerns for growth. 📉
Investors may find the dividend yield of 2.94% insufficient given the high valuation, especially when compared to peers like Ajanta Pharma and Gland Pharma. Immediate market sentiment may be negatively impacted.
Not investment advice. For informational purposes only.